DENISE SIQUEIRA VANNI
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
- Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease(2021) STEFANO, Jose Tadeu; GUEDES, Laura Vilar; SOUZA, Arthur Alencar Arrais de; VANNI, Denise Siqueira; ALVES, Venancio Avancini Ferreira; CARRILHO, Flair Jose; LARGURA, Alvaro; ARRESE, Marco; OLIVEIRA, Claudia P.Introduction/aims: Liver fibrosis assessment is a key issue in the evaluation of nonalcoholic fatty liver disease (NAFLD) patients. In the present study, we aimed to validate a noninvasive marker panel to assess significant and advanced fibrosis in these patients. Method: 126 biopsy-proven NAFLD patients were included. NAFLD diagnosis was based on histological criteria. Fibrosis stages were determined according to NASH-Clinical Research Network criteria. Clinical and laboratorial data were collected during the interval of three months before or after liver biopsy. Histological fibrosis stages were classified as significant fibrosis (F2-F4) and advanced fibrosis (F3-F4). Five serum biomarkers [hyaluronic acid (HA), collagen type IV (cIV), procollagen type III (PC III), laminin (LN) and cholylglycine (CG)] were assessed by chemiluminescence immunoassays. Results: Most patients were female (61.61%), mean age: 55.7 +/- 9.13 years old and mean BMI was 32.1 +/- 5.9 kg/m(2). Prevalence of diabetes, dyslipidemia, arterial hypertension, and metabolic syndrome was 68.75%, 82.29%, 63.54% and 81.05%, respectively. Patients with cIV above 30 ng/mL had a 5.57-times (IC: 1.86-16.69) the chance of having significant fibrosis and 7.61-times (IC: 2.27-25.54) the chance of having advanced fibrosis versus patients with values below 30 ng/mL. HA, PC III, LN and CG did not detect the presence of significant and advanced fibrosis. The AUROC of clV for detection of significant (0.718) and advanced fibrosis (0.791) was better than that of other serum biomarkers. Conclusion: Type 4 collagen could predict the presence of significant and advanced fibrosis in NAFLD patients and it would be a useful tool in routine clinical practice. (C) 2020 Fundacion Clinica Medica Sur, A.C.
conferenceObject Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population(2020) ZAMBRANO-HUAILLA, Rommel; GUEDES, Laura; SOUZA, Arthur A. Arrais de; STEFANO, Jose Tadeu; MARCIANO, Sebastian; YVAMOTO, Erika; MICHALCZUK, Matheus Truccolo; VANNI, Denise Siqueira; RODRIGUEZ, Hernan; CARRILHO, Flair Jose; ALVARES-DA-SILVA, Mario Reis; ARRESE, Marco; GADANO, Adrian; MIRANDA, Adelina Lozano; OLIVEIRA, Claudia- Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population(2020) ZAMBRANO-HUAILLA, Rommel; GUEDES, Laura; STEFANO, Jose Tadeu; SOUZA, Arthur A. Arrais de; MARCIANO, Sebastian; YVAMOTO, Erika; MICHALCZUK, Matheus Truccolo; VANNI, Denise Siqueira; RODRIGUEZ, Hernan; CARRILHO, Flair Jose; ALVARES-DA-SILVA, Mario Reis; GADANO, Adrian; ARRESE, Marco; MIRANDA, Adelina Lozano; OLIVEIRA, Claudia P.Introduction and aims: Several non-invasive scoring systems have been developed and validated worldwide to predict the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, information about the performance of these systems in Latin American populations is scarce. Our aim was to evaluate the performance of the Hepamet Fibrosis Score, Fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) in a mixed Latin American group of NAFLD patients. Methods: Clinical, laboratory and liver biopsy data collected from 379 biopsy-proven NAFLD patients from Latin American tertiary health centers were reviewed. Histological fibrosis stages were classified using the Kleiner score. Accuracy was determined, and new fibrosis score thresholds were calculated to better compare the performances of non-invasive tests and to explore their usefulness in excluding fibrosis. Results: The distribution of fibrosis stages among the sample population was as follows: F0 (45%), Fl (27%), F2 (8%), F3 (16%) and F4 (4%). Using modified thresholds, the areas under the ROC curves (AUROC) for Hepamet and FIB-4 (0.73 and 0.74, respectively) to detect significant fibrosis were higher than that of NFS (0.58). However, the AUROCs of the three scores were not significantly different in advanced fibrosis and cirrhosis. To exclude fibrosis, we calculated lower cutoffs than standard thresholds for Hepamet, FIB-4 and NFS with similar performances. Conclusion: Thresholds of non-invasive fibrosis scores (Hepamet, FIB-4 and NFS) can be modified to maximize diagnostic accuracy in Latin American patients with NAFLD. (C) 2020 Fundacion Clinica Medica Sur, A.C.